Wednesday , 13 December 2017

Home » RESOURCES » INVESTING » Merck’s stock falls after disclosing government probe into asthma drug pricing

Merck’s stock falls after disclosing government probe into asthma drug pricing

Merck & Co. Inc.’s stock dropped 1.5% in midday trade Friday, after the drug maker disclosed in a filing late Thursday that it had received a civil investigative demand from the U.S. Attorney’s office. The demand requests information related to the contracting and pricing of its Dulera Inhalation Aerosol asthma treatment with certain pharmacy benefit managers and Medicare Part D plans. Merck said in the filing that it was cooperating with the investigation. The stock has lost 4.5% year to date, while the Dow Jones Industrial Average has ticked up 0.1%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Merck’s stock falls after disclosing government probe into asthma drug pricing Reviewed by on . Merck & Co. Inc.'s stock dropped 1.5% in midday trade Friday, after the drug maker disclosed in a filing late Thursday that it had received a civil investig Merck & Co. Inc.'s stock dropped 1.5% in midday trade Friday, after the drug maker disclosed in a filing late Thursday that it had received a civil investig Rating:
scroll to top